1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Osteoporosis Therapeutics Industry

Global Osteoporosis Therapeutics Industry

  • April 2021
  • 340 pages
  • ID: 5817617
  • Format: PDF
  • Global Industry Analysts


Table of Contents


Timely market intelligence is paramount in these uncertain times!

We launched an impact survey to update this project with timely insights during 2020. Update frequency will depend upon evolving market conditions and executive opinions. Our participants are executives driving strategy, marketing, sales and product management at competitive companies worldwide. All updates during the rest of the year are complimentary to clients!

- The global market for Osteoporosis Therapeutics is projected to reach US$13.3 billion by 2025, driven by rising awareness over the growing problem of osteoporosis and the ensuing emphasis on early diagnosis and treatment. With the percentage share of people aged 60 plus in the global population mix forecast to reach 21.5% from the current 12.7%, burden of osteoporosis will increase significantly accounting for over 75% of all fractures among the elderly. Although largely preventable, fractures result in long-term injuries, severe pain, long-term disability and high mortality. In the Europe, India, Japan and the United States over 150 million people live with osteoporosis, a number poised to rise significantly in the coming years. Medical emphasis on prevention and early diagnosis will therefore gain prominence providing the cornerstone for growth in the market. As losses in bone mineral density (BMD) is high in the elderly, aging population remains a key growth catalyst, with the risk of osteoporotic hip, vertebral and wrist fracture tripling with age. Economic burden of osteoporotic fractures (OFs) will grow bigger in sync with the aging population growth from 729.3 million people in the age group 65+ in 2020 to over 852.5 million by 2025. The cost of long-term disability from osteoporosis is huge since over 25% of elderly suffering from hip fracture will require permanent nursing home care. Also driving prevalence rates are factors such as rising incidence of vitamin D deficiencies, anorexia nervosa, growing cancer epidemic and increase in the number of patients undergoing chemotherapy and/or using glucocorticoids both of which tend to accelerate the loss of bone mineral density.
- The scenario offers a robust outlook for osteoporosis therapeutics. Osteoporosis therapeutics are mainly targeted at reducing the risk of fractures, and are categorized into two main drug categories, named antiresorptive or anabolic. Antiresorptive drugs reduce bone resorption and include mainly bisphosphonates, estrogens, estrogen agonist/ antagonists [EAAs], calcitonin, and denosumab. Anabolic drugs work by increasing bone formation and include teriparatide. Few of the approved drugs for osteoporosis include EVISTA (Selective Estrogen-Receptor Modulator (SERM); DUAVIVE (Estrogen and Selective Estrogen-Receptor Modulator (SERM); FORTEO (Parathyroid Hormone); ACLASTA/ACTONEL (Bisphosphonates); PROLIA (RANK ligand inhibitor); CLIMARA (Hormonal Therapy - Transdermal). Bisphosphonates represent the largest category of drugs for the treatment of osteoporosis and is recommended as the first line of treatment for the prevention of osteoporosis in postmenopausal women, men, and GIO patients. The market also stands to benefit from growing movement in the medical community over the need for further research for safe use of long-term osteoporosis drug therapies for fracture prevention. This will help attract funding support and will speed up the development of new treatments. The United States and Europe represent large markets worldwide with a combined share of 67.2% of the market. China ranks as the fastest growing market with a CAGR of 5.9% over the analysis period supported by attractive reimbursement policies. The national health system and private insurers together reimburse over 75% to 875% of inpatient osteoporosis treatments and 35% to 45% of outpatient care. Traditional Chinese medicine enjoys over is 80% reimbursement.

- Select Competitors (Total 53 Featured) -
  • Alergan Plc.
  • Amgen, Inc.
  • Chugai pharmaceutical
  • Daiichi Sankyo Co., Ltd.
  • Egalet Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.;

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Lupus Nephritis (Immunology) - Drugs in Development, 2021

  • $ 2000
  • April 2021
  • 90 pages

Lupus Nephritis (Immunology) - Drugs in Development, 2021 Summary Lupus Nephritis (Immunology) - Drugs in Development, 2021 provides an overview of the Lupus Nephritis pipeline landscape. The report ...

  • World
  • Genitourinary System Disease
  • Musculoskeletal Disorder
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on